ClinicalTrials.gg
CompletedNCT06193434Updated Sep 2, 2025

A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

A Phase 1 interventional study of IBI356 for MAD and Dupilumab for MAD in Healthy Participants and Atopic Dermatitis Patients, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
132nd of 191
99 · median 163
Started
2024
with 36 others
Phase 1
39 of 207
15 open now
Registered
97th of 207
by date

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 132nd largest by enrollment of the 191 interventional ones that give a count, is one of 37 that started in 2024, is one of 39 in phase 1, and was the 97th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

03

Conditions studied

  • Healthy Participants
  • Atopic Dermatitis Patients

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy participants:

    1. Aged 18 to 45 years,
    2. Weight 50 to 120 kgs,
    3. Good physical and mental health based on medical history, physical examination, clinical laboratory, , and vital signs, as judged by the Investigator.
    4. No during the trial and within 6 months after SAD doses, and adequate measures can be taken.
  2. Atopic dermatitis:

    1. Aged 18 to 75 years,
    2. (BMI): 18.0 - 32.0 kg/m2,
    3. Atopic Dermatitis (AD) for 1 year or longer at Baseline,
    4. Eczema Area and Severity Index (EASI) of 16 or higher at baseline,
    5. Investigator Global Assessment (IGA) of 3 or 4 at baseline,
    6. AD involvement of 10 percent or more of body surface area at Baseline,
    7. Documented history, within 1 year before Baseline, of either inadequate response to topical treatments or inadvisability of topical treatments,
    8. Must have applied a stable dose of topical bland emollient at least twice daily for at least 7 consecutive days before Baseline.

Exclusion criteria

Exclusion Criteria:

  1. History of relevant drug allergies.
  2. Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (for example, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments
  3. Healthy participants:

    1. History of alcohol abuse or drug addiction within 1 year before screen,
    2. Positive drug and alcohol screen at screening.
  4. Atopic dermatitis:

    1. Having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, was likely to require / immunomodulating drugs treatment(s) during the first 4 weeks of study treatment:
    2. Treatment with topical (TCS) or topical calcineurin inhibitors (TCI) within 1 week before the baseline visit.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    IBI356 for Single ascending dose (SAD)

    Drug: IBI356 for SAD

  • Experimental
    IBI356 for Multiple ascending dose (MAD)

    Drug: IBI356 for MAD

  • Placebo comparator
    Placebo for MAD

    Drug: Placebo for MAD

  • Active comparator
    Dupilumab for MAD

    Drug: Dupilumab for MAD

  • Placebo comparator
    Placebo for SAD

    Drug: Placebo for SAD

Interventions

  • DrugIBI356 for MAD

    Receive IBI356 in a multiple dose.

  • DrugDupilumab for MAD

    Active comparator

  • DrugIBI356 for SAD

    Receive IBI356 in a single dose.

  • DrugPlacebo for SAD

    Receive placebo in a single dose.

  • DrugPlacebo for MAD

    Receive placebo in a multiple dose.

This study also gives Dupilumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Occurrence of Adverse Event (AE) in SAD study.

    Time frame: Baseline to Week 20

  2. Occurrence of Adverse Event (AE) in MAD study.

    Time frame: Baseline to Week 36

  3. Occurrence of Serious Adverse Event (SAE) in SAD study.

    Time frame: Baseline to Week 20

  4. Occurrence of Serious Adverse Event (SAE) in MAD study.

    Time frame: Baseline to Week 36

  5. Changes in blood pressure mmHg (as a measure of safety and tolerability) in SAD study.

    Time frame: Baseline to Week 20

  6. Changes in blood pressure mmHg (as a measure of safety and tolerability) in MAD study.

    Time frame: Baseline to Week 36

  7. Changes in respiratory rate measured as breaths per minute (as a measure of safety and tolerability) in SAD study.

    Time frame: Baseline to Week 20

  8. Changes in respiratory rate measured as breaths per minute (as a measure of safety and tolerability) in MAD study.

    Time frame: Baseline to Week 36

  9. Changes in heart rate bpm (as a measure of safety and tolerability) in SAD study.

    Time frame: Baseline to Week 20

  10. Changes in heart rate bpm (as a measure of safety and tolerability) in MAD study.

    Time frame: Baseline to Week 36

  11. Changes in tympanic temperature °C in SAD study.

    Time frame: Baseline to Week 20

  12. Changes in tympanic temperature °C in MAD study.

    Time frame: Baseline to Week 36

  13. Changes in electrocardiograms PR, QR, QRS and QT intervals (as a measure of safety and tolerability) in SAD study.

    Time frame: Baseline to Week 20

  14. Changes in electrocardiograms PR, QR, QRS and QT intervals (as a measure of safety and tolerability) in MAD study.

    Time frame: Baseline to Week 36

Secondary outcomes

  1. Area under the concentration time curve from time 0 to last observation (AUC 0-t).

    Time frame: Baseline to Week 16

  2. Maximum observed concentration (Cmax) after infusion.

    Time frame: Baseline to Week 16

  3. Systemic clearance after infusion (CL).

    Time frame: Baseline to Week 16

  4. Volume of distribution during the terminal phase after infusion(Apparent volume of distribution, V).

    Time frame: Baseline to Week 16

  5. Elimination half-life during the terminal phase after infusion(Half-life, t1/2).

    Time frame: Baseline to Week 16

  6. To assess immunogenicity: production of anti-drug antibodies (ADA) following SAD and Multiple ascending dose(MAD) doses.

    Time frame: Baseline to Week 16

07

Study locations

1 site
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality 200443, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Aug 2025, 19 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 19 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Jan 5, 2024
StartActual
Jan 5, 2024
Primary completionActual
Aug 20, 2025
CompletionActual
Aug 20, 2025
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06193434
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jan 5, 2024
Primary completion
Aug 20, 2025
Completion
Aug 20, 2025
Last update
Sep 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion